Ignite Creation Date:
2025-12-24 @ 11:55 PM
Ignite Modification Date:
2026-02-25 @ 7:21 PM
Study NCT ID:
NCT01842451
Status:
COMPLETED
Last Update Posted:
2015-12-29
First Post:
2013-04-24
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C
Sponsor:
Vertex Pharmaceuticals Incorporated
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-06
Start Date Type:
None
Primary Completion Date:
2014-05
Primary Completion Date Type:
ACTUAL
Completion Date:
2014-05
Completion Date Type:
ACTUAL
First Submit Date:
2013-04-24
First Submit QC Date:
None
Study First Post Date:
2013-04-29
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2015-11-20
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2015-11-30
Last Update Post Date:
2015-12-29
Last Update Post Date Type:
ESTIMATED